GE Healthcare has agreed to acquire Thermo Fisher Scientific’s HyClone™ cell culture business, which includes media and sera that are used to manufacture biological therapies and vaccines, as well as its gene modulation and magnetic beads businesses for approximately US$1.06 B. The three businesses reported combined revenue of approximately US$250 M in 2013. Thermo Fisher put the assets up for sale in November 2013 to expedite European approval of its pending US$13.6 B purchase of Life Technologies, which was agreed in April 2013.